Clinical Trial Update: Open-Label Extension Study to ZPE-202 [Phase 2]

View source ↗

Summary

A Phase 2 open-label extension study (ZPE-202) for endometriosis has been withdrawn; no further development for this study is indicated by the sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• Proellex (telapristone acetate)
• ZPE-202

Snippet

Sponsor: Repros Therapeutics Inc. | Conditions: Endometriosis | Phase 2 | Status: WITHDRAWN